NIH: mRNA vaccine generates immune response in older adults
An experimental mRNA vaccine for the COVID-19 virus generated a strong immune response in older adults in a phase 1 clinical trial, who generally tolerated it well, the National Institutes of Health reports.
The National Institute of Allergy and Infectious Diseases developed the vaccine with Moderna Inc.
The phase 1 trial began in March and later added 40 healthy adults over age 55, who received two doses and will be followed for a year to monitor the long-term effects of the vaccine. According to the researchers, the results support testing the vaccine in older adults in an ongoing large Phase 3 trial.
Related News Articles
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…